The cholangiopathies

Mayo Clinic Proceedings

Volumn 90, Issue 6, 2015, Pages 791-800

  Lazaridis, Konstantinos N ^a   Larusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEZAFIBRATE; OBETICHOLIC ACID; SOMATOSTATIN DERIVATIVE; URSODEOXYCHOLIC ACID;

BILE DUCT ATRESIA; BILE DUCT CARCINOMA; BILE DUCT DISEASE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLON RESECTION; CONCEPTUAL FRAMEWORK; CYSTIC FIBROSIS; EPIGENETICS; GENETIC PREDISPOSITION; HEPATOPORTOENTEROSTOMY; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; MEDICAL LITERATURE; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SURGICAL APPROACH; SURVIVAL RATE; BILE DUCT DISEASES; CHOLANGIOCARCINOMA; EPITHELIUM CELL; INTRAHEPATIC BILE DUCT; LIVER DISEASES; PHYSIOLOGY;

BILE DUCT DISEASES; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; EPITHELIAL CELLS; HUMANS; LIVER DISEASES;

EID: 84931281668     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.03.017     Document Type: Review

References (80)

1. Y.B. Yoon, L.R. Hagey, A.F. Hofmann, D. Gurantz, E.L. Michelotti, and J.H. Steinbach Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents Gastroenterology 90 4 1986 837 852
2. United Network for Organ Sharing website. http://www.unos.org. Accessed July 11, 2014.
3. UNOS Transplant Living website. http://www.transplantliving.org. July 11, 2014.
4. K.N. Lazaridis, M. Strazzabosco, and N.F. Larusso The cholangiopathies: disorders of biliary epithelia Gastroenterology 127 5 2004 1565 1577
5. P.T. Bogert, and N.F. LaRusso Cholangiocyte biology Curr Opin Gastroenterol 23 3 2007 299 305
6. D. Alvaro, M.G. Mancino, and S. Glaser Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver Gastroenterology 132 1 2007 415 431
7. M. Marzioni, S.S. Glaser, H. Francis, J.L. Phinizy, G. LeSage, and G. Alpini Functional heterogeneity of cholangiocytes Semin Liver Dis 22 3 2002 227 240
8. V. Cardinale, Y. Wang, and G. Carpino Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets Hepatology 54 6 2011 2159 2172
9. G. Carpino, V. Cardinale, and P. Onori Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages J Anat 220 2 2012 186 199
10. S.P. O'Hara, J.H. Tabibian, P.L. Splinter, and N.F. LaRusso The dynamic biliary epithelia: molecules, pathways, and disease J Hepatol 58 3 2013 575 582
11. V.J. Desmet Ductal plates in hepatic ductular reactions: hypothesis and implications, I: types of ductular reaction reconsidered Virchows Arch 458 3 2011 251 259
12. J.J. Marin, L. Bujanda, and J.M. Banales MicroRNAs and cholestatic liver diseases Curr Opin Gastroenterol 30 3 2014 303 309
13. E.J. Topol Individualized medicine from prewomb to tomb Cell 157 1 2014 241 253
14. K. Boonstra, U. Beuers, and C.Y. Ponsioen Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review J Hepatol 56 5 2012 1181 1188
15. B.D. Juran, and K.N. Lazaridis Environmental factors in primary biliary cirrhosis Semin Liver Dis 34 3 2014 265 272
16. G.M. Hirschfield Diagnosis of primary biliary cirrhosis Best Pract Res Clin Gastroenterol 25 6 2011 701 712
17. K.D. Lindor, M.E. Gershwin, R. Poupon, M. Kaplan, N.V. Bergasa, and E.J. Heathcote Primary biliary cirrhosis Hepatology 50 1 2009 291 308
18. T.H. Karlsen, M. Vesterhus, and K.M. Boberg Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis Aliment Pharmacol Ther 39 3 2014 282 301
19. D.E. Jones, F.E. Watt, J.V. Metcalf, M.F. Bassendine, and O.F. James Familial primary biliary cirrhosis reassessed: a geographically-based population study J Hepatol 30 3 1999 402 407
20. G.M. Hirschfield, X. Liu, and C. Xu Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants N Engl J Med 360 24 2009 2544 2555
21. G.M. Hirschfield, X. Liu, and Y. Han Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis Nat Genet 42 8 2010 655 657
22. X. Liu, P. Invernizzi, and Y. Lu Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis Nat Genet 42 8 2010 658 660
23. G.F. Mells, J.A. Floyd, and K.I. Morley Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis Nat Genet 43 4 2011 329 332
24. L. Wang, F.S. Wang, C. Chang, and M.E. Gershwin Breach of tolerance: primary biliary cirrhosis Semin Liver Dis 34 3 2014 297 317
25. - anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis Hepatology 56 2 2012 687 697
26. - umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes Hepatology 55 1 2012 173 183
27. B.D. Juran, E.J. Atkinson, J.J. Larson, E.M. Schlicht, and K.N. Lazaridis Common genetic variation and haplotypes of the anion exchanger SLC4A2 in primary biliary cirrhosis Am J Gastroenterol 104 6 2009 1406 1411
28. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases J Hepatol 51 2 2009 237 267
29. E.A. Tsochatzis, K.S. Gurusamy, C. Gluud, and A.K. Burroughs Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines J Hepatol 51 6 2009 1084 1085 author reply 1085-1086
30. C. Lammert, B.D. Juran, and E. Schlicht Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients J Gastroenterol 49 10 2014 1414 1420
31. C. Corpechot, L. Abenavoli, and N. Rabahi Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 3 2008 871 877
32. T. Kumagi, M. Guindi, and S.E. Fischer Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis Am J Gastroenterol 105 10 2010 2186 2194
33. A. Pares, L. Caballeria, and J. Rodes Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 3 2006 715 720
34. C. Corpechot Primary biliary cirrhosis and bile acids Clin Res Hepatol Gastroenterol 36 suppl 1 2012 S13 S20
35. A. Honda, T. Ikegami, and M. Nakamuta Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid Hepatology 57 5 2013 1931 1941
36. S. Lens, M. Leoz, L. Nazal, M. Bruguera, and A. Pares Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid Liver Int 34 2 2014 197 203
37. M.G. Silveira, J.A. Talwalkar, K.D. Lindor, and R.H. Wiesner Recurrent primary biliary cirrhosis after liver transplantation Am J Transplant 10 4 2010 720 726
38. P. Charatcharoenwitthaya, S. Pimentel, and J.A. Talwalkar Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation Liver Transpl 13 9 2007 1236 1245
39. R.F. Liermann Garcia, C. Evangelista Garcia, P. McMaster, and J. Neuberger Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center Hepatology 33 1 2001 22 27
40. J. Neuberger, B. Gunson, S. Hubscher, and P. Nightingale Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation Liver Transpl 10 4 2004 488 491
41. E.Q. Sanchez, M.F. Levy, and R.M. Goldstein The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation Transplantation 76 11 2003 1583 1588
42. J.E. Eaton, J.A. Talwalkar, K.N. Lazaridis, G.J. Gores, and K.D. Lindor Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management Gastroenterology 145 3 2013 521 536
43. R. Chapman, J. Fevery, and A. Kalloo Diagnosis and management of primary sclerosing cholangitis Hepatology 51 2 2010 660 678
44. T.H. Karlsen, A. Franke, and E. Melum Genome-wide association analysis in primary sclerosing cholangitis Gastroenterology 138 3 2010 1102 1111
45. E. Melum, A. Franke, and C. Schramm Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci Nat Genet 43 1 2011 17 19
46. J.Z. Liu, J.R. Hov, and T. Folseraas Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis Nat Genet 45 6 2013 670 675
47. P. Rausch, A. Rehman, and S. Kunzel Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype Proc Natl Acad Sci U S A 108 47 2011 19030 19035
48. A.J. Grant, P.F. Lalor, M. Salmi, S. Jalkanen, and D.H. Adams Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease Lancet 359 9301 2002 150 157
49. F. Rodier, J.P. Coppe, and C.K. Patil Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion Nat Cell Biol 11 8 2009 973 979
50. J.H. Tabibian, S.P. O'Hara, P.L. Splinter, C.E. Trussoni, and N.F. LaRusso Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis Hepatology 59 6 2014 2263 2275
51. K.D. Lindor Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. Ursodiol for primary sclerosing cholangitis N Engl J Med 336 10 1997 691 695
52. K.D. Lindor, K.V. Kowdley, and V.A. Luketic High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 3 2009 808 814
53. B. Fosby, T.H. Karlsen, and E. Melum Recurrence and rejection in liver transplantation for primary sclerosing cholangitis World J Gastroenterol 18 1 2012 1 15
54. E. Alabraba, P. Nightingale, and B. Gunson A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts Liver Transpl 15 3 2009 330 340
55. S.M. Rowe, S. Miller, and E.J. Sorscher Cystic fibrosis N Engl J Med 352 19 2005 1992 2001
56. K. Moyer, and W. Balistreri Hepatobiliary disease in patients with cystic fibrosis Curr Opin Gastroenterol 25 3 2009 272 278
57. T. Lamireau, S. Monnereau, S. Martin, J.E. Marcotte, M. Winnock, and F. Alvarez Epidemiology of liver disease in cystic fibrosis: a longitudinal study J Hepatol 41 6 2004 920 925
58. C. Colombo, A. Crosignani, and P.M. Battezzati Liver involvement in cystic fibrosis J Hepatol 31 5 1999 946 954
59. C.L. Mack, A.G. Feldman, and R.J. Sokol Clues to the etiology of bile duct injury in biliary atresia Semin Liver Dis 32 4 2012 307 316
60. C. Petersen, and M. Davenport Aetiology of biliary atresia: what is actually known? Orphanet J Rare Dis 8 1 2013 128
61. B.R. Lu, S.M. Brindley, R.M. Tucker, C.L. Lambert, and C.L. Mack α-Enolase autoantibodies cross-reactive to viral proteins in a mouse model of biliary atresia Gastroenterology 139 5 2010 1753 1761
62. S.M. Brindley, A.M. Lanham, F.M. Karrer, R.M. Tucker, A.P. Fontenot, and C.L. Mack Cytomegalovirus-specific T-cell reactivity in biliary atresia at the time of diagnosis is associated with deficits in regulatory T cells Hepatology 55 4 2012 1130 1138
63. A.G. Miethke, V. Saxena, P. Shivakumar, G.E. Sabla, J. Simmons, and C.A. Chougnet Post-natal paucity of regulatory T cells and control of NK cell activation in experimental biliary atresia J Hepatol 52 5 2010 718 726
64. M.M. Garcia-Barcelo, M.Y. Yeung, and X.P. Miao Genome-wide association study identifies a susceptibility locus for biliary atresia on 10q24.2 Hum Mol Genet 19 14 2010 2917 2925
65. E.A. Tsai, C.M. Grochowski, and K.M. Loomes Replication of a GWAS signal in a Caucasian population implicates ADD3 in susceptibility to biliary atresia Hum Genet 133 2 2014 235 243
66. J.J. Tseng, M.S. Lai, M.C. Lin, and Y.C. Fu Stool color card screening for biliary atresia Pediatrics 128 5 2011 e1209 e1215
67. C.H. Hsiao, M.H. Chang, and H.L. Chen Universal screening for biliary atresia using an infant stool color card in Taiwan Hepatology 47 4 2008 1233 1240
68. T. Masyuk, A. Masyuk, and N. LaRusso Cholangiociliopathies: genetics, molecular mechanisms and potential therapies Curr Opin Gastroenterol 25 3 2009 265 271
69. L. Al-Bhalal, and M. Akhtar Molecular basis of autosomal recessive polycystic kidney disease (ARPKD) Adv Anat Pathol 15 1 2008 54 58
70. J.M. Banales, T.V. Masyuk, S.A. Gradilone, A.I. Masyuk, J.F. Medina, and N.F. LaRusso The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD) Hepatology 49 1 2009 160 174
71. T.V. Masyuk, A.I. Masyuk, V.E. Torres, P.C. Harris, and N.F. Larusso Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate Gastroenterology 132 3 2007 1104 1116
72. M.C. Hogan, T.V. Masyuk, and L.J. Page Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease J Am Soc Nephrol 21 6 2010 1052 1061
73. M.L. DeOliveira, S.C. Cunningham, and J.L. Cameron Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution Ann Surg 245 5 2007 755 762
74. S.A. Khan, S. Emadossadaty, and N.G. Ladep Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 56 4 2012 848 854
75. J.E. Everhart, and C.E. Ruhl Burden of digestive diseases in the United States, part III: liver, biliary tract, and pancreas Gastroenterology 136 4 2009 1134 1144
76. N. Razumilava, and G.J. Gores Classification, diagnosis, and management of cholangiocarcinoma Clin Gastroenterol Hepatol 11 1 2013 13 21
77. B.R. Kipp, L.M. Stadheim, and S.A. Halling A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures Am J Gastroenterol 99 9 2004 1675 1681
78. T. Nakazawa, I. Naitoh, K. Hayashi, K. Miyabe, S. Simizu, and T. Joh Diagnosis of IgG4-related sclerosing cholangitis World J Gastroenterol 19 43 2013 7661 7670
79. S. Darwish Murad, W.R. Kim, and D.M. Harnois Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers Gastroenterology 143 1 2012 88 98
80. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 14 2010 1273 1281